Beam Therapeutics Announces Key R&D Appointments
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced key leadership appointments, including the promotion of Manmohan Singh, Ph.D., from vice president to senior vice president of pharmaceutical sciences and delivery technologies, and the appointment of Christine Swenson as senior vice president of regulatory affairs. “As we advance our new class of precision genetic medicines closer to the clinic, we are focused on continuing to expand the scientific leadership at Beam,” said John Evans, chief executive officer of Beam. “We look forward to benefitting from Chris and Mano’s decades of experience in developing innovative new therapies at leading companies. Their leadership will help us deliver precise, predictable and efficient base editing medicines that have the potential to become life-long cures for patients with serious diseases.” Dr. Sing
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid CongressGlobeNewswire
- Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target lowered by analysts at Barclays PLC from $42.00 to $33.00. They now have an "equal weight" rating on the stock.MarketBeat
- Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss [Yahoo! Finance]Yahoo! Finance
BEAM
Earnings
- 5/7/24 - Beat
BEAM
Sec Filings
- 5/7/24 - Form 10-Q
- 5/7/24 - Form 8-K
- 4/29/24 - Form 4
- BEAM's page on the SEC website